Eli Lilly (LLY) reported second quarter results which exceeded the consensus estimate. Shares of Eli Lilly were trading up about 5% in the pre-market trading on upbeat results and the encouraging outlook as well as the company’s decision to separate Elanco Animal Health business as a separate public company. Non-GAAP earnings increased to $1.50 per … Continue reading Eli Lilly beats Q2 estimates; stock surges